Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ALLSTATE CLINICAL LABORATORIES, LLC

NPI: 1831648195 · OWINGS MILLS, MD 21117 · Clinical Medical Laboratory · NPI assigned 09/28/2016

$912K
Total Medicaid Paid
10,786
Total Claims
5,812
Beneficiaries
3
Codes Billed
2018-01
First Month
2018-05
Last Month

Provider Details

Authorized OfficialHAYAT, HASSAN (MANAGING MEMBER)
NPI Enumeration Date09/28/2016

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 10,786 $912K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 4,115 2,257 $510K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 4,078 2,199 $232K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2,593 1,356 $169K